Human Immunodeficiency Virus Type 1 (HIV 1) Market

Human Immunodeficiency Virus Type 1 (HIV 1) Market Snapshot (2023 to 2033)

The global human immunodeficiency virus type 1 (HIV 1) market size is expected to reach a valuation of USD 34.83 Billion in 2023 and is projected to exhibit a compound annual growth rate (CAGR) of 6% from 2023 to 2033.

HIV is a virus that targets the body's cells that aid in the battle against infectious disease, making the individual more sensitive to other illnesses and infections. HIV is a retrovirus comprising RNA rather than DNA. It attacks the immune system (T lymphocytes and other white blood cells with CD4 receptors on their surfaces) in the body.

According to the Institute for Health Metrics and Evaluation, the market's expansion can be attributed to the rising incidence rate of HIV-1 infection, which, unlike the fatality rate from this viral illness, has not updated significantly over the years. It affected approximately 37 million individuals around the world. Moreover, only half of this population has access to antiretroviral therapeutic interventions for disease control. HIV-1 is the more frequent of the two varieties of the human immunodeficiency virus, accounting for roughly 96% of all infections worldwide. Considering the aforementioned facts and figures, the market is projected to exhibit a good rate of growth.

Report Attribute	Details
Expected Market Value (2023)	USD 34.83 Billion
Anticipated Forecast Value (2033)	USD 62.37 Billion
Projected Growth Rate (2023 to 2033)	6% CAGR

2018 to 2022 Human Immunodeficiency Virus Type 1 (HIV 1) Demand Analysis vs. Forecast 2023 to 2033

The global population of individuals infected with this virus rapidly increased during the historical period. As a result of the lack of sufficient diagnosis and treatment infrastructure, the disease has heavily impacted poor and developing countries on a wide scale. From 2018 to 2022, sales witnessed significant growth, registering a CAGR of 1.6%.

The incidence of HIV is soaring at an alarming rate. Based on the World Health Organization (WHO), a guesstimated 33.0 million people are infected with HIV. This has resulted in higher public awareness, which is leading to a rise in test methods. Over the forecast period, this will result in an increase in demand for HIV medicines with higher efficacy for the treatment and care of the disease.

Which are Some Prominent Drivers of the Human Immunodeficiency Virus Type 1 (HIV 1) Market?

Burgeoning HIV/AIDS Incidence to Push Market Growth

One of the key contributing factors expected to propel market growth is the rising prevalence of HIV/AIDS, particularly in Africa. According to the World Health Organization (WHO), an estimated 33.0 million people were living with HIV infection in 2021, with 1.5 million [1.1 million-2.0 million] new HIV infections.

According to WHO, women and girls constituted 54% of all HIV-positive people. This large patient population in various regions is driving up demand for antiretroviral (ARV) drugs. Furthermore, the government is working to improve HIV-1 patients' access to treatment and assessment. This is expected to fuel the global HIV-1 market.

Combined efforts of the government and several NGOs to propel the market growth

The deliberate initiatives of the government and multiple NGOs to supply at-risk individuals with better exposure to disease diagnosis and treatment for infected patients are key factors driving the HIV-1 market growth.

Numerous companies, including Cipla, Inc. and Gilead Sciences, Inc., have also implemented diagnosis education programs to lessen the detrimental ramifications of infectious diseases. The potential growth of this market is heavily reliant on the unfulfilled assessment and treatment needs in African and Asian countries.

What are the Challenges Projected to be Faced by the Market?

Scarcity of Treatment Access and Lack of awareness of HIV Infection Status May Stifle Growth

Despite advances in technology development, enhanced scientific knowledge of HIV, and the affordability of therapeutic approaches, some detaining aspects are reducing future growth. Many individuals who are HIV-positive or at risk of becoming HIV-positive are unable to get timely treatment access. Besides that, there is no treatment for this virus.

As reported by the Joint United Nations Program on HIV/AIDS (UNAIDS), for instance, diagnosis metrics are distributed unevenly around the world. The lack of sufficient treatment options continues to be a challenge in middle-income and emerging nations, stifling the expansion of the HIV1 market.

Region-Wise Insights

What Makes North America the Largest Market for Human Immunodeficiency Virus Type 1 (HIV 1)?

North America's dominance is due to the high prevalence of HIV infection

With a market share of USD 21 Billion in 2022, North America dominated the market. This region's dominance is credited to the rising incidence of HIV infection in the US citizenry. Based on a study performed by the Centers for Disease Control (CDC) in 2021, an estimated 1.2 million people were living with HIV at the end of 2018.

With such a large patient population, the requirement for HIV drugs skyrockets. The population's consciousness is another aspect that contributes to regional growth. Furthermore, the presence of prominent players providing new HIV medications for the treatment of HIV1 transmission would augment the market growth.

Why is Asia Pacific Considered a Lucrative Region for the Human Immunodeficiency Virus Type 1 (HIV 1) Market?

Because of its dense population, the Asia Pacific market is the fastest-growing region

Owing to the highly populous nations, like China and India, with a huge proportion of HIV patients, the Asia Pacific market is predicted to be the fastest-growing market with the largest CAGR over the forecast period. Moreover, the vast number of therapeutic interventions and financial support from the private sector and medical companies are expected to propel the industry.

For example, Gilead Sciences, Inc., one of the world's biggest antiretroviral drug manufacturers, declared a USD 1.4 Million funding for its 'Gilead Asia Pacific Rainbow Grant Program' in Asia Pacific in December 2020. The program consists of Gilead's initiative to strengthen public-private collaborations in the Asia Pacific region in order to tackle the difficulties posed by HIV-infected patients.

Category-Wise Insights

Which Type Leads the Market for Human Immunodeficiency Virus Type 1 (HIV 1)?

Integrase inhibitors are preferred as first-line treatments for recently diagnosed patients

As the primary line of treatment for HIV, the integrase inhibitors segment held the second-highest market share in 2021, supporting the growth of the segment. Integrase inhibitors are advised as initial treatments for newly diagnosed HIV infection by the International AIDS Society (IAS).

The non-nucleoside reverse transcriptase inhibitors (NRTIs) segment has the smallest share of the market due to significantly fewer requirements for this drug class compared to the late innovative pharmaceutical launches

Start-ups in the HIV 1 Treatment Domain

• Y Combinator is a technology start-up activator in the USA that was founded in March 2005. The Immunity Project is creating a free HIV/AIDS vaccine using a novel approach involving data analysis and machine learning. It is one of seven charitable organizations in the current batch of the elite accelerator program Y Combinator.
• Argu Soft India Limited is a start-up company that was founded on August 21, 2000. It is headquartered in Gandhi Nagar, Gujarat, India. ArguSoft developed a health app to inhibit AIDS transmission from mother to child and is collaborating with the Indian government and charitable groups to combat the disease efficaciously.

Market Competition

Key players in the Human Immunodeficiency Virus Type 1 (HIV 1) market are AbbVie, Inc, Boehringer, and Ingelheim GmbH. Bristol-Myers Squibb Company, Cipla, Inc, Genentech, Inc, Gilead Sciences, Inc., Merck & Co., Inc., ViiV Healthcare, GlaxoSmithKline, Sanofi.

• In July 2021 - Unitaid and the Clinton Health Access Initiative, Inc. (CHAI) declared a pricing contract with the medical company Hetero Labs LTD to create darunavir combined with ritonavir (DRV/r) obtainable as a second-line treatment for HIV patients in low and moderate-income nations for USD 210 per patient/year.
• Gilead Sciences Inc. and Merck revealed a partnership deal in March 2021 to co-develop and co-commercialize lengthy HIV treatment. Gilead's investigational capsid inhibitor lenacapavir and Merck's investigational nucleoside reverse transcriptase translocation inhibitor islatravir will be combined to produce a two-drug regimen for HIV.
• In January 2021 - HIV Cabenuva, an injectable drug approved by the US Food and Drug Administration for the treatment of human immunodeficiency virus type 1 (HIV) infections in adults, was developed by ViiV Healthcare.

Report Scope

Report Attribute	Details
Expected Market Value (2023)	USD 34.83 Billion
Anticipated Forecast Value (2033)	USD 62.37 Billion
Projected Growth Rate (2023 to 2033)	6% CAGR
Base Year for Estimation	2022
Historical Data	2018 to 2022
Forecast Period	2023 to 2033
Quantitative Units	Revenue in USD Billion and CAGR from 2023 to 2033
Report Coverage	Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis
Segments Covered	Drug Class, Region
Regions Covered	North America; Latin America; Europe; Asia Pacific; Middle East & Africa
Key Countries Profiled	USA, Canada, Brazil, Mexico, Mexico, Germany, UK, France, Spain, Italy, Russia, China, Japan, India, South Korea, Australia, Saudi Arabia, South Africa, UAE, Israel
Key Companies Profiled	AbbVie Inc.; Boehringer Ingelheim GmbH; Bristol-Myers Squibb Company; Cipla Inc.; Genentech Inc.; Gilead Sciences, Inc.; Merck & Co. Inc.; ViiV Healthcare; GlaxoSmithKline; Sanofi
Customization	Available Upon Request

Table of Content

• 1. Executive Summary | Human Immunodeficiency Virus Type 1 (HIV 1) Market
• 2. Market Overview
• 3. Market Background
• 4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033
• 5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Class
  • 5.1. Nucleoside-Analog Reverse Transcriptase Inhibitors
  • 5.2. Non-Nucleoside Reverse Transcriptase Inhibitors
  • 5.3. Entry and Fusion Inhibitors
  • 5.4. Protease Inhibitors
  • 5.5. Integrase Inhibitors
  • 5.6. Coreceptor Antagonists
• 6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region
  • 6.1. North America
  • 6.2. Latin America
  • 6.3. Europe
  • 6.4. Asia Pacific
  • 6.5. Middle East and Africa
• 7. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
• 8. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
• 9. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
• 10. Asia Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
• 11. Middle East and Africa Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
• 12. Key Countries Market Analysis
• 13. Market Structure Analysis
• 14. Competition Analysis
  • 14.1. AbbVie, Inc.
  • 14.2. Boehringer Ingelheim GmbH
  • 14.3. Bristol-Myers Squibb Company
  • 14.4. Cipla, Inc.
  • 14.5. Genentech, Inc.
  • 14.6. Gilead Sciences, Inc.
  • 14.7. Merck & Co., Inc.
  • 14.8. ViiV Healthcare
  • 14.9. GlaxoSmithKline
  • 14.10. Sanofi
• 15. Assumptions & Acronyms Used
• 16. Research Methodology